Ligand Pharmaceuticals (LGND) Equity Average (2011 - 2026)

Ligand Pharmaceuticals has disclosed Equity Average across 16 years of filings, most recently posting $1.0 billion for Q1 2026.

• Equity Average for Q1 2026 came in at $1.0 billion, up 23.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 23.89% YoY), and the FY2025 annual result was $923.8 million, up 20.65% from the prior year.
• Equity Average came in at $1.0 billion for Q1 2026 at Ligand Pharmaceuticals, up from $983.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $1.0 billion in Q1 2026 to a low of $621.9 million in Q1 2023.
• The 5-year median for Equity Average is $807.2 million (2022), against an average of $790.7 million.
• Across the five-year window, Equity Average dropped 22.95% in 2023 and grew 23.89% in 2026, its largest moves.
• Ligand Pharmaceuticals' Equity Average stood at $706.9 million in 2022, then slipped by 3.18% to $684.4 million in 2023, then climbed by 22.12% to $835.8 million in 2024, then increased by 17.69% to $983.7 million in 2025, then gained by 2.4% to $1.0 billion in 2026.
• The last three Equity Average figures came in at $1.0 billion (Q1 2026), $983.7 million (Q4 2025), and $888.7 million (Q3 2025), per Business Quant data.